326 related articles for article (PubMed ID: 36568830)
1. Inhaled Bacteriophage Therapy for Multi-Drug Resistant
Winzig F; Gandhi S; Lee A; Würstle S; Stanley GL; Capuano I; Neuringer I; Koff JL; Turner PE; Chan BK
Yale J Biol Med; 2022 Dec; 95(4):413-427. PubMed ID: 36568830
[TBL] [Abstract][Full Text] [Related]
2. Phage therapy against Achromobacter xylosoxidans lung infection in a patient with cystic fibrosis: a case report.
Hoyle N; Zhvaniya P; Balarjishvili N; Bolkvadze D; Nadareishvili L; Nizharadze D; Wittmann J; Rohde C; Kutateladze M
Res Microbiol; 2018 Nov; 169(9):540-542. PubMed ID: 29777836
[TBL] [Abstract][Full Text] [Related]
3. Bacteriophage Therapy of Multidrug-resistant Achromobacter in an 11-Year-old Boy With Cystic Fibrosis Assessed by Metagenome Analysis.
Bradley JS; Hajama H; Akong K; Jordan M; Stout D; Rowe RS; Conrad DJ; Hingtgen S; Segall AM
Pediatr Infect Dis J; 2023 Sep; 42(9):754-759. PubMed ID: 37343220
[TBL] [Abstract][Full Text] [Related]
4. Compounding
Cobián Güemes AG; Le T; Rojas MI; Jacobson NE; Villela H; McNair K; Hung SH; Han L; Boling L; Octavio JC; Dominguez L; Cantú VA; Archdeacon S; Vega AA; An MA; Hajama H; Burkeen G; Edwards RA; Conrad DJ; Rohwer F; Segall AM
Viruses; 2023 Jul; 15(8):. PubMed ID: 37632008
[No Abstract] [Full Text] [Related]
5. A Case of Phage Therapy against Pandrug-Resistant
Lebeaux D; Merabishvili M; Caudron E; Lannoy D; Van Simaey L; Duyvejonck H; Guillemain R; Thumerelle C; Podglajen I; Compain F; Kassis N; Mainardi JL; Wittmann J; Rohde C; Pirnay JP; Dufour N; Vermeulen S; Gansemans Y; Van Nieuwerburgh F; Vaneechoutte M
Viruses; 2021 Jan; 13(1):. PubMed ID: 33466377
[TBL] [Abstract][Full Text] [Related]
6. Stability Considerations for Bacteriophages in Liquid Formulations Designed for Nebulization.
Flint R; Laucirica DR; Chan HK; Chang BJ; Stick SM; Kicic A
Cells; 2023 Aug; 12(16):. PubMed ID: 37626867
[TBL] [Abstract][Full Text] [Related]
7. Phage steering of antibiotic-resistance evolution in the bacterial pathogen,
Gurney J; Pradier L; Griffin JS; Gougat-Barbera C; Chan BK; Turner PE; Kaltz O; Hochberg ME
Evol Med Public Health; 2020; 2020(1):148-157. PubMed ID: 34254028
[TBL] [Abstract][Full Text] [Related]
8. Bacteriophage therapy for infections in CF.
Chan BK; Stanley G; Modak M; Koff JL; Turner PE
Pediatr Pulmonol; 2021 Feb; 56 Suppl 1():S4-S9. PubMed ID: 33434411
[TBL] [Abstract][Full Text] [Related]
9. Bacteriophage steering of
Ruest MK; Supina BSI; Dennis JJ
J Bacteriol; 2023 Oct; 205(10):e0019623. PubMed ID: 37791751
[TBL] [Abstract][Full Text] [Related]
10. Combining bacteriophages with cefiderocol and meropenem/vaborbactam to treat a pan-drug resistant Achromobacter species infection in a pediatric cystic fibrosis patient.
Gainey AB; Burch AK; Brownstein MJ; Brown DE; Fackler J; Horne B; Biswas B; Bivens BN; Malagon F; Daniels R
Pediatr Pulmonol; 2020 Nov; 55(11):2990-2994. PubMed ID: 32662948
[TBL] [Abstract][Full Text] [Related]
11. Fitness Trade-Offs between Phage and Antibiotic Sensitivity in Phage-Resistant Variants: Molecular Action and Insights into Clinical Applications for Phage Therapy.
Fujiki J; Nakamura K; Nakamura T; Iwano H
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958612
[TBL] [Abstract][Full Text] [Related]
12. Evolutionary Dynamics between Phages and Bacteria as a Possible Approach for Designing Effective Phage Therapies against Antibiotic-Resistant Bacteria.
Hasan M; Ahn J
Antibiotics (Basel); 2022 Jul; 11(7):. PubMed ID: 35884169
[TBL] [Abstract][Full Text] [Related]
13. Bacteriophage genome engineering for phage therapy to combat bacterial antimicrobial resistance as an alternative to antibiotics.
Usman SS; Uba AI; Christina E
Mol Biol Rep; 2023 Aug; 50(8):7055-7067. PubMed ID: 37392288
[TBL] [Abstract][Full Text] [Related]
14. Fitness Trade-Offs Resulting from Bacteriophage Resistance Potentiate Synergistic Antibacterial Strategies.
Mangalea MR; Duerkop BA
Infect Immun; 2020 Jun; 88(7):. PubMed ID: 32094257
[TBL] [Abstract][Full Text] [Related]
15. A simple solid media assay for detection of synergy between bacteriophages and antibiotics.
Khong E; Oh JJ; Jimenez JM; Liu R; Dunham S; Monsibais A; Rhoads A; Ghatbale P; Garcia A; Cobián Güemes AG; Blanc AN; Chiu M; Kuo P; Proost M; Kline A; Aslam S; Schooley RT; Whiteson K; Fraley SI; Pride DT
Microbiol Spectr; 2024 May; 12(5):e0322123. PubMed ID: 38526142
[TBL] [Abstract][Full Text] [Related]
16. Challenges and Promises for Planning Future Clinical Research Into Bacteriophage Therapy Against
Rossitto M; Fiscarelli EV; Rosati P
Front Microbiol; 2018; 9():775. PubMed ID: 29780361
[TBL] [Abstract][Full Text] [Related]
17. Bacteriophages as a potential substitute for antibiotics: A comprehensive review.
Kushwaha SO; Sahu SK; Yadav VK; Rathod MC; Patel D; Sahoo DK; Patel A
Cell Biochem Funct; 2024 Apr; 42(3):e4022. PubMed ID: 38655589
[TBL] [Abstract][Full Text] [Related]
18. Prospects of Inhaled Phage Therapy for Combatting Pulmonary Infections.
Wang X; Xie Z; Zhao J; Zhu Z; Yang C; Liu Y
Front Cell Infect Microbiol; 2021; 11():758392. PubMed ID: 34938668
[TBL] [Abstract][Full Text] [Related]
19. Phage Therapy of Mycobacterium Infections: Compassionate Use of Phages in 20 Patients With Drug-Resistant Mycobacterial Disease.
Dedrick RM; Smith BE; Cristinziano M; Freeman KG; Jacobs-Sera D; Belessis Y; Whitney Brown A; Cohen KA; Davidson RM; van Duin D; Gainey A; Garcia CB; Robert George CR; Haidar G; Ip W; Iredell J; Khatami A; Little JS; Malmivaara K; McMullan BJ; Michalik DE; Moscatelli A; Nick JA; Tupayachi Ortiz MG; Polenakovik HM; Robinson PD; Skurnik M; Solomon DA; Soothill J; Spencer H; Wark P; Worth A; Schooley RT; Benson CA; Hatfull GF
Clin Infect Dis; 2023 Jan; 76(1):103-112. PubMed ID: 35676823
[TBL] [Abstract][Full Text] [Related]
20. Developing Phage Therapy That Overcomes the Evolution of Bacterial Resistance.
Oromí-Bosch A; Antani JD; Turner PE
Annu Rev Virol; 2023 Sep; 10(1):503-524. PubMed ID: 37268007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
